Hudson Bay Capital Management
TVTX icon

Hudson Bay Capital Management’s Travere Therapeutics TVTX Stock Holding History

Hudson Bay Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,200
Closed -$1.31M – 1703
2026
Q1 		$1.31M Sell
44,200
-856,100
-95% -$25.6M ﹤0.01% 841
2025
Q4 		$34.4M Buy
900,300
+584,000
+185% +$19M 0.11% 163
2025
Q3 		$7.56M Buy
+316,300
New +$5.95M 0.03% 430

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hudson Bay Capital Management's TVTX Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 6,520 shares — an estimated $194K sold.

Hudson Bay Capital Management first reported a position in TVTX in Q2 2019 and held it in 5 quarters. The position peaked at $6.82M in Q2 2023. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 6,520 Travere Therapeutics shares in Q2 2026, an estimated $194K.
  • Hudson Bay Capital Management first reported a position in Travere Therapeutics in Q2 2019 and held it in 5 quarters.
  • Hudson Bay Capital Management's Travere Therapeutics position peaked at $6.82M in Q2 2023.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.